Literature DB >> 22866128

Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo.

Norifumi Tsutsumi1, Shunji Kohnoe, Hideto Sonoda, Atsushi Guntani, Tatsuya Rikimaru, Ken-Ichi Taguchi, Morimasa Tomikawa, Yoshihiro Kakeji, Hideaki Nakashima, Yoshihiko Maehara.   

Abstract

Protein-bound polysaccharide-K (PSK) is a biological response modifier that possesses antitumor effects against various tumors. Although an inflammatory response has been considered to play an important role in the development of colorectal cancer, the anti-inflammatory effect of PSK has yet to be elucidated. An inflammatory bowel disease (IBD)-induced colorectal tumor model with 1.2-dimethyl hydrazine (DMH) and dextran sodium sulfate (DSS) was used to examine the effects of PSK on tumor suppression and survival. Although 90% of the mice that were not treated with PSK developed colitic tumors, oral administration of PSK suppressed tumor formation by less than 30%. Although deaths associated with DSS-induced melena were observed, PSK significantly reduced mortality. In conclusion, the present study showed that PSK not only suppressed colorectal tumor formation in the DMH+DSS-induced IBD model, but also improved the survival rate, indicating that anti-inflammatory activity is one of the mechanisms for the antitumor effects of PSK.

Entities:  

Year:  2011        PMID: 22866128      PMCID: PMC3408101          DOI: 10.3892/ol.2011.336

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Celecoxib for the prevention of sporadic colorectal adenomas.

Authors:  Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Scott D Solomon; KyungMann Kim; Jie Tang; Rebecca B Rosenstein; Janet Wittes; Donald Corle; Timothy M Hess; G Mabel Woloj; Frédéric Boisserie; William F Anderson; Jaye L Viner; Donya Bagheri; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Gary B Gordon; Ernest T Hawk
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

2.  Celecoxib for the prevention of colorectal adenomatous polyps.

Authors:  Nadir Arber; Craig J Eagle; Julius Spicak; István Rácz; Petr Dite; Jan Hajer; Miroslav Zavoral; Maria J Lechuga; Paola Gerletti; Jie Tang; Rebecca B Rosenstein; Katie Macdonald; Pritha Bhadra; Robert Fowler; Janet Wittes; Ann G Zauber; Scott D Solomon; Bernard Levin
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

3.  Development of colonic neoplasms and expressions of p53 and p21 proteins in experimental colitis of mice induced by dextran sulfate sodium.

Authors:  F Takesue; D Korenaga; T Yao; A Kabashima; K Sugimachi
Journal:  J Exp Clin Cancer Res       Date:  2001-09

4.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

5.  Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model.

Authors:  Isao Okayasu; Masahiro Yamada; Tetuo Mikami; Tsutomu Yoshida; Jun Kanno; Toshifumi Ohkusa
Journal:  J Gastroenterol Hepatol       Date:  2002-10       Impact factor: 4.029

Review 6.  Krestin (PSK).

Authors:  S Tsukagoshi; Y Hashimoto; G Fujii; H Kobayashi; K Nomoto; K Orita
Journal:  Cancer Treat Rev       Date:  1984-06       Impact factor: 12.111

7.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

8.  Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide.

Authors:  M Kato; K Hirose; M Hakozaki; M Ohno; Y Saito; R Izutani; J Noguchi; Y Hori; S Okumoto; D Kuroda
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

Review 9.  Beta-catenin and the morphogenesis of colorectal cancer.

Authors:  Thomas Brabletz; Andreas Jung; Thomas Kirchner
Journal:  Virchows Arch       Date:  2002-04-27       Impact factor: 4.064

10.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

Authors:  Andrew T Chan; Shuji Ogino; Charles S Fuchs
Journal:  N Engl J Med       Date:  2007-05-24       Impact factor: 91.245

View more
  1 in total

Review 1.  Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.

Authors:  Yoshihiko Maehara; Shunichi Tsujitani; Hiroshi Saeki; Eiji Oki; Keiji Yoshinaga; Yasunori Emi; Masaru Morita; Shunji Kohnoe; Yoshihiro Kakeji; Tokujiro Yano; Hideo Baba
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.